Lumos Diagnostics (ASX: LDX) wins full U.S. Medicare reimbursement for FebriDx

Lumos Diagnostics Holdings Ltd (ASX: LDX) has secured complete Medicare Administrative Contractor (MAC) reimbursement recognition for its flagship FebriDx test, a pivotal achievement that establishes nationwide reimbursement eligibility across all U.S. jurisdictions. The announcement, made on November 21, 2025, confirms that National Government Services (NGS), the final Medicare Administrative Contractor (MAC) required for full coverage, has listed FebriDx on the U.S. Centers for Medicare & Medicaid Services (CMS) Clinical Lab Fee Schedule (CLFS) at US$41.38 per test.

This final addition completes Lumos Diagnostics’ push to obtain coverage across all seven MACs, marking a strategic inflection point in the Australian healthcare firm’s U.S. market entry. The development also reinforces FebriDx’s commercial pathway at a time when Lumos Diagnostics’ share price has surged by over 566% in the past year, driven in part by accelerating investor confidence and expanding diagnostic market validation.

What makes full MAC recognition so significant for FebriDx’s U.S. rollout?

Securing reimbursement coverage from all seven U.S. MACs means FebriDx is now officially eligible for Medicare payment in all 50 states. NGS, which oversees Medicare processing for major states such as Illinois, Minnesota, and Wisconsin, as well as key northeastern regions including New York and New England, was the final jurisdiction required to complete Lumos Diagnostics’ national reimbursement framework.

With this milestone, Lumos Diagnostics has eliminated one of the most critical hurdles for widespread adoption. Reimbursement recognition through CMS is a prerequisite for large-scale diagnostic deployment in primary care and urgent care networks that serve Medicare beneficiaries. The unified MAC coverage effectively ensures that Medicare, which accounts for roughly 20% to 24% of the U.S. payor mix, can now consistently reimburse healthcare providers for using FebriDx to distinguish between viral and bacterial respiratory infections.

Previous milestones included recognition from CGS, Novitas, Palmetto, First Coast Service Options, Noridian Healthcare Solutions, and WPS Health Solutions, each of which was secured earlier in 2025. The addition of NGS to this list closes the loop on CMS’s national MAC reimbursement network.

How does this move influence Medicaid and private insurance alignment?

Medicare’s reimbursement framework often acts as a pricing benchmark for Medicaid and private insurers. Lumos Diagnostics has acknowledged that MAC recognition not only impacts Medicare billing but also provides leverage for further payor discussions. Medicare Advantage and managed Medicaid plans routinely use CMS rates when building their own payment models, which means FebriDx’s listing at US$41.38 could translate into broader commercial payor adoption over time.

To accelerate this alignment, Lumos Diagnostics has partnered with reimbursement consultancy PRO-spectus, which will work closely with MACs and other payors to support integration of FebriDx coverage into internal policy systems. The company also emphasized its commitment to helping MACs transition from fee schedule listing to the creation of formal written reimbursement policies, which would streamline provider billing and reduce claim rejections.

The groundwork being laid with CMS is thus expected to extend beyond public programs and catalyze decisions from commercial payors as well. With diagnostic stewardship and value-based healthcare gaining traction, FebriDx’s point-of-care capabilities align with emerging insurance incentives that prioritize early, accurate, and cost-effective diagnostic decision-making.

How did markets respond to the MAC coverage milestone?

Lumos Diagnostics shares surged 15.79% to AUD 0.22 on the ASX following the announcement, bringing its market capitalization to approximately AUD 173.18 million. The trading session saw volumes exceed 7 million shares, suggesting strong retail and institutional interest. Over the past year, LDX has delivered a staggering 566.67% return, making it one of the best-performing healthcare stocks on the ASX during this period.

The sharp rally reflects investor optimism that Lumos Diagnostics has now completed the critical regulatory and reimbursement groundwork to pursue meaningful commercial scale in the United States. Analysts monitoring the diagnostic firm note that the absence of a price-to-earnings ratio is consistent with its current pre-revenue stage, but the company’s operational milestones, combined with favorable U.S. policy tailwinds, have started to shift investor focus toward near-term monetization potential.

Institutional sentiment is likely to track future developments such as Medicaid coverage onboarding, private insurer agreements, and quarterly revenue ramp metrics. Any forward-looking commentary or evidence of provider uptake could act as a catalyst for further stock re-rating.

What is FebriDx and how does it align with current diagnostic priorities?

FebriDx is a Lumos-branded point-of-care diagnostic test that helps differentiate between viral and bacterial respiratory infections using two biomarkers: CRP (C-reactive protein) and MxA (Myxovirus resistance protein A). The test uses a single fingerstick blood sample and delivers results in about 10 minutes, making it suitable for real-time clinical decisions in outpatient settings.

The diagnostic’s relevance is growing amid rising concerns over antibiotic resistance and the need to reduce unnecessary prescriptions. FebriDx has shown potential to support antimicrobial stewardship programs by helping clinicians avoid prescribing antibiotics for viral infections, a scenario that still drives significant overuse in the U.S. healthcare system.

FebriDx’s inclusion in the CMS CLFS now positions it as a viable frontline diagnostic in value-based care initiatives, where outcomes, efficiency, and test utility are tightly linked to reimbursement. Industry observers believe the product could gain traction not just in primary care clinics but also in urgent care, telehealth-assisted triage, and mobile healthcare services where fast, accurate infectious disease diagnostics are in high demand.

What is Lumos Diagnostics’ roadmap following reimbursement success?

With MAC reimbursement secured, Lumos Diagnostics is now pivoting toward operational scale and commercial execution. Key next steps include working with each MAC to develop and finalize written reimbursement policies that ensure consistency across regional Medicare offices. This process is critical for providers, who often hesitate to adopt new diagnostics without policy-backed billing guarantees.

In parallel, Lumos will collaborate with PRO-spectus to support policy integration with Medicaid and private insurers. These engagements will be focused on translating Medicare recognition into actual payer coverage determinations, which could be decisive in accelerating hospital and clinic adoption.

The U.S. reimbursement achievement also puts Lumos Diagnostics in a stronger position to consider additional international expansion, new test development, or strategic licensing arrangements, each of which could further diversify revenue streams and reinforce its point-of-care diagnostics platform.

Looking ahead, Lumos Diagnostics is also expected to invest in U.S.-based sales expansion, clinical education, and digital support infrastructure. Establishing clinical champions and onboarding early provider networks could help validate FebriDx in real-world settings, offering proof points for broader health system partnerships.

What are the key takeaways from Lumos Diagnostics’ full Medicare coverage announcement?

• Lumos Diagnostics Holdings Ltd (ASX: LDX) has secured 100% Medicare Administrative Contractor (MAC) coverage for its FebriDx test, achieving a U.S. reimbursement milestone across all seven MAC jurisdictions.

• The final approval came from National Government Services (NGS), which covers high-volume regions such as New York, New England, Illinois, Minnesota, and Wisconsin.

• FebriDx is now listed on the U.S. Centers for Medicare & Medicaid Services (CMS) Clinical Lab Fee Schedule at US$41.38 per test, unlocking consistent billing and payment eligibility nationwide.

• Medicare represents approximately 20% to 24% of the U.S. healthcare payor mix, and CMS coverage serves as a pricing benchmark for Medicaid and commercial insurance payors.

• Lumos Diagnostics will now work with MACs to develop formal written policies, providing billing predictability for providers and accelerating claims processing.

• Reimbursement consultancy PRO-spectus will support policy integration with Medicaid and private insurers to further expand FebriDx access.

• The FebriDx test, which differentiates viral from bacterial respiratory infections using CRP and MxA biomarkers, supports efforts to reduce antibiotic overuse and enhance diagnostic efficiency.

• Lumos Diagnostics shares jumped nearly 16% following the announcement, and the stock has delivered over 566% return in the past 12 months.

• The company is shifting focus to U.S. commercialization efforts, including provider education, MAC engagement, and private payor partnerships.

• Analysts and investors are closely watching the firm’s ability to convert reimbursement access into revenue growth and secure adoption in outpatient and urgent care settings.